Skip to main content

Table 1 Patient demographics and disease characteristics

From: Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study

  Number (%) or mean (SD) or median (IQR: 25th–75th)
Country, n (%)  
 Australia 217 (15%)
 China 222 (16%)
 Indonesia 98 (7%)
 Philippines 124 (9%)
 Singapore 219 (15%)
 Taiwan 294 (21%)
 Thailand 250 (18%)
Ethnicity, n (%)  
 Caucasian 116 (8%)
 Chinese 699 (49%)
 Filipino 132 (9%)
 Indonesian 101 (7%)
 Thai 254 (18%)
 Malay 37 (3%)
 Vietnamese/Cambodian 22 (2%)
 Indian/Sri Lankan 35 (2%)
 Othera 28 (2%)
Gender, n (%)  
 Female 1329 (93%)
Highest attained education levelb  
 Primary 241 (17%)
 Secondary 548 (38%)
 Tertiary 607 (42%)
Age at diagnosis (years) 31.1 (12.2)
Disease duration (years) 9.2 (7.7)
SLICC-DI score 0 (0–1)
Damage presentc 498 (35%)
PGA at enrollment 0.5 (0.2–1)
Mild flare 170 (12%)
Severe flare 100 (7%)
SLEDAI-2 K 4 (2–6)
Current CNS activityd 9 (0.6%)
Current vasculitisd 23 (1.6%)
Current renal activityd 369 (25.9%)
Current musculoskeletal activityd 119 (8.4%)
Current cutaneous activityd 273 (19.2%)
Current serositisd 12 (0.8%)
Lupus low disease activity state (LLDAS) 593 (42%)
Number (%) of patients taking prednisoloneg 1167 (82%)
Taking immunosuppressante 762 (53.5%)
Taking antimalarialf 1044 (73.3%)
  1. aOther includes Hispanic, African, other South-East Asian, Pacific Islander and mixed ethnicity. bPercent present shown in table, percent absent and missing not shown in table. cSLICC-DI >0. dActive based on non-zero SLEDAI-2 K scores in organ domains as indicated. eEither methotrexate, azathioprine, mycophenolate, leflunomide, cyclosporine, cyclophosphamide (in the last 6 months), rituximab (in the last 6 months) and/or belimumab (in the last 6 months). fEither hydroxychloroquine or chloroquine. Abbreviations: SLE systemic lupus erythematosus, SLEDAI SLE disease activity index, SLICC Systemic Lupus International Collaborating Clinics, DI damage index, PGA physician global assessment, CNS central nervous system, CVA cerebrovascular accident
  2. gMean dose (SD) 12 mg (13.7)